Ireland
Cosmo Pharmaceuticals is a biotechnology and pharmaceutical company based in Ireland, founded in 1996. The company's slogan "We develop innovative treatments that address significant unmet clinical needs" underscores its commitment to pioneering medical solutions.
Cosmo Pharmaceuticals focuses on developing novel treatments for gastro-intestinal diseases and colon infections. One of their key objectives is to reduce the incidence of Colorectal Cancer (CRC) by enhancing the detection rate of pre-cancerous lesions during colonoscopies.
Notably, the company has received a substantial investment of $25.00M in post-IPO debt infusion on 04 June 2020 from Acacia Pharma, signaling investor confidence in its mission and potential.
With a diverse portfolio of specialty products, Cosmo Pharmaceuticals is actively involved in drugs manufacturing and innovative research, accentuating its commitment to improving clinical outcomes and positively impacting patients' lives.
For more information, interested parties can visit their website at www.cosmopharma.com/.
